The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of postoperative ctDNA dynamics on eligibility for the ALTAIR randomized trial in patients with colorectal cancer: Implications for clinical trial enrollment.
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Vasily Aushev
Employment - Natera
Stock and Other Ownership Interests - Natera
Travel, Accommodations, Expenses - Natera
 
Jun Watanabe
Honoraria - Covidien; Johnson & Johnson/MedTech; Lilly; Takeda; TERUMO
Research Funding - Covidien (Inst); Stryker (Inst); TERUMO (Inst)
 
Yusuke Takahashi
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly
 
Nobuhisa Matsuhashi
Honoraria - Abbott Japan; Alfresa Pharma Corporation; Amco; Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; EA Pharma; Eisai; Guardant Health; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; Kyowa Kirin; Lilly Japan; MC Medical; Merck KGaA; Miyarisan pharmaceutical; MSD; Novartis; Olympus Marketing, Inc.; Ono Pharmaceutical; Stryker; Stryker; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Viatris; Yakult Honsha; Zeria Pharmaceutical
Research Funding - Covidien (Inst); e-NA Biotec Inc. (Inst); EPS Corporation (Inst); JMS (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Toray Industries (Inst)
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Manabu Shiozawa
Speakers' Bureau - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Keiji Hirata
No Relationships to Disclose
 
Yuji Miyamoto
Speakers' Bureau - Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Kentaro Yamazaki
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Kun-Huei Yeh
Honoraria - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; DSI/AZ; MSD; MSD; Novartis; Ono Pharmaceutical; Pfizer; Pierre Fabre; Takeda
Travel, Accommodations, Expenses - Merck; Ono Pharmaceutical; Pfizer; Takeda
 
Adham Jurdi
Employment - Natera
Stock and Other Ownership Interests - Agenus; Iovance Biotherapeutics; natera; Verastem
 
Saori Mishima
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Exact Sciences
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Guardant Health; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - MSD K.K; Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); Daiichi Sankyo/UCB Japan (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Hiroya Taniguchi
Honoraria - Ono Yakuhin; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst)
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda